Product Information

RISPERIDONE ER 37.5 MG VIAL is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $556.6988 per EA under NDC 00480134208. Its NADAC has been published 114 times since Jun 19, 2024.

FDA first approved this application on Dec 5, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for RISPERIDONE ER 37.5 MG VIAL has been published 114 times since Jun 19, 2024, and over the history we have for it it has declined 22.3%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.